Healthcare resource utilization during the follow-up period.

1L: first-line; 2L: second-line; 3L: third-line; Dex: dexamethasone; DLBCL: diffuse large B-cell lymphoma; ER: emergency room; ICU: intensive care unit; LOS: length of stay; Mono: monotherapy; NOS: not otherwise specified; R: rituximab; R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone; R-CVP: rituximab plus cyclophosphamide, vincristine, and prednisone; SD: standard deviation. aImmunotherapy, targeted therapy, or hormone therapy. (XLSX)